- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04753944
Probiotics Therapy of Mood Disorders
Probiotics Therapy: a New Approach to Therapy of Mood Disorders in Perimenopausal Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim: The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
The study hypothesis: By using periodic probiotics therapy it is possible to positively influence the mood of women with depressive syndromes. These efforts focus on the improvement of the functioning of the gut barrier and gut-brain axis. In practice, such activities should lead to the reduction in the dysfunction of the barrier, the reduction of endotoxemia and the concentration of neurotoxic metabolites of tryptophan (in blood) with the simultaneous increase in the content of butyric acid that has a neuroprotective effect.
The of the trial: intervention, cohort, randomized, double-blind, using placebo. A multi-strain probiotic will also be provided ( Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 or maize starch, maltodextrins and vegetable protein/placebo).
The applied method of study:
- a controlled dietary intervention that includes probiotics therapy; the verification of the past nutritional pattern (the Food Frequency Questionnaire); anthropometric measurements;
- psychiatric studies: the evaluation of sleep disorders (the Athens insomnia scale) and mood (the Beck scale), and the worsening of depression (the Hamilton scale);
- biochemical studies: the content of short chain fatty acids (in the stool);
- cytometric studies (B-type lymphocytes' panel, T-type lymphocytes' panel, regulatory T cells' panel);
- genetic (the microbiome of bacteria in the stool, pyrosequencing);
- chromatographic (the derivatives of tryptophan e.g., kynurenine, anthranilic acid, kynureic acid, 3-hydroxykynurenine, 5-hydroxytryptophan, serotonin).
Currently, there is an urgent problem to develop recommendations regarding the nutrition and probiotics therapy that could complement the therapy of women with mood disorders. If the achieved results confirm the study hypothesis, it will be possible to:
- better understand the pathomechanism of mood disorders in the perimenopausal period;
- develop a holistic strategy for depressive disorders in women in the menopause period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zachodniopomorskie
-
Szczecin, Zachodniopomorskie, Poland, 70-393
- Pomeranian Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- must presence of mood disorders confirmed by Beck scale (more than 10 points)
- must be able to swallow tablets
Exclusion Criteria:
- individuals that had prescribed antibiotics, proton pump inhibitors, or probiotics in the 6 months preceding the study (eg. inflammatory bowel syndrome)
- circulatory disorders patients
- diagnosed coagulopathies,
- diagnosed respiratory disease
- inflammatory bowel disease patients
- addicted to alcohol
- addicted to psychoactive substances,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Probiotic group
Patients will be introduced for 5 weeks with probiotic therapy (in the study group).
They will take Ecologic®Barrier (Winclove Probiotics BV, Amsterdam, The Netherlands), consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58.
The probiotic dose is going to be 4 capsules daily (one capsule contains 500 million CFUs of living probiotic strains).
The treatment will be administered two times a day, during breakfast and supper.
The probiotic formula will be Provided by polish distributor of Winclove products, namely Sanprobi sp.
z o. o. sp.
k
|
The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
Other Names:
|
PLACEBO_COMPARATOR: Placebo group
Patients will be introduced for 5 weeks with placebo that consist of maize starch, maltodextrins and vegetable protein.
The placebo dose is going to be 4 capsules daily (one capsule).
The treatment will be administered two times a day, during breakfast and supper.
|
Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein.
The placebo dose is going to be 4 capsules daily.
The treatment will be administered two times a day, during breakfast and supper.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dietary intervention
Time Frame: 5 weeks
|
The verification of the past nutritional pattern (will be asses by Food Freguency Questionnarie).
The indicate frequency of food consumption, respondents could choose one of six categories (next converted by researcher into daily frequency): never or very rarely (0 times/day), once a month or less (0.025 times/day), several times a month (0.1 times/day), several times a week (0.571 times/day), daily (1 time/day), or a few times a day (2 times/day)
|
5 weeks
|
Anthropometric measurements
Time Frame: 5 weeks
|
The verification of body mass during the study will be asses by body mass index (BMI).
In order of this, we will measure the height (outcome in cm).
BMI will be calculated by dividing body weight (in kilograms) by height squared (in meters).i
Finally BMI will be presented in kg/m2.
|
5 weeks
|
Depression intensity mesurements
Time Frame: 5 weeks
|
Depression intensity will be asses by the Hamilton Rating Scale for Depression (HRSD).Unit HRSD ( 0-7 not depressed, 8-13 mild depression; 14-18 moderate depression (mild); 19-22 moderate depression; > 23 severe depression)
|
5 weeks
|
The biochemical changes in stool
Time Frame: 5 weeks
|
Observation of biochemical changes short fatty acids (SCFAs) concentration before and after the intervention (SCFA in ng/ml)
|
5 weeks
|
The cytometric studies
Time Frame: 5 weeks
|
Observation of a change in Mean Fluorescence Intensity (FSC) of lymphocytes B and regulatory T cells before and after intervention in flow cytometry.
Assessments by median: midpoint of the population (middle channel)).
|
5 weeks
|
The stool microbiota changes
Time Frame: 5 weeks
|
Changes in gut microbiota composition and metabolism (16 SrRNA bacterial genomic, bacterial metabolites) at enrollment and at the end-point ( gut microbiota will be asses in Operational taxonomic units (OTUs))
|
5 weeks
|
Insomnia studies
Time Frame: 3 months
|
Assessments using unique measurements Athens insomnia scale ( 0 to < 6 means no insomnia; more than 6 points indicated diagnosis of insomnia)
|
3 months
|
The Kynureine Pathway
Time Frame: 3 months
|
The changes in the tryptophan pathway derivatives before and after intervention will be measured.
( we assess metabolites of kynurenine pathway e.g. 5 HT, HIAA, KYN will be asses by HPLC (in ng/ml)
|
3 months
|
Collaborators and Investigators
Investigators
- Study Director: Jerzy Samochowiec, prof, MD, Pomeranian Medical University in Sczecin
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pomeranian Medical Univeristy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Lawson Health Research InstituteTerminated
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
Clinical Trials on Active Comparator: Probiotic
-
TiumBio Co., Ltd.RecruitingEndometriosisCzechia, Italy, Russian Federation, Poland, Ukraine
-
Lindenwood UniversityCompletedImmune and Recovery Modulating Impact of Probiotic Supplementation After Intense Resistance ExerciseMuscle Damage | Muscular Fatigue | Immune Markers | Complete Blood Count (CBC) With Platelet Differentials | Muscular Force Production | Countermovement Jump | Muscular SorenessUnited States
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
Eisai Inc.Not yet recruiting
-
Stanford UniversityRecruitingTreatment Resistant Depression | Bipolar II Disorder, Most Recent Episode Major Depressive | Current Depressive EpisodeUnited States
-
NestléCompletedMild to Moderate Levels of StressSwitzerland
-
United States Naval Medical Center, San DiegoTerminatedPTSD - Post Traumatic Stress Disorder
-
Case Western Reserve UniversityHighland Instruments, Inc.Recruiting
-
Biopolis S.L.Korott, S.L.CompletedDermatitis, AtopicSpain
-
Eisai Inc.CompletedHealthy | Drug AbuseCanada